🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07149922
Starting soon Not applicable

Early Blood Pressure Intervention After Coiling or Clipping for Subarachnoid Hemorrhage

NCT07149922 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tiantan Hospital
Phase
Not applicable
Started
2025-08-31
Last updated
2025-09-02

Condition(s) studied

Aneurysmal Subarachnoid HemorrhageAneurysmal Subarachnoid Hemorrhage (aSAH)

Investigational drug(s) / intervention(s)

Blood pressure was regulated within the normal target management rangeBlood pressure was regulated within the elevated target management range

Blood pressure was regulated within the normal target management range: Blood pressure monitoring was initiated immediately upon the patient's return to the intensive care unit (ICU) postoperatively, followed by randomization. Blood pressure management was guided by systolic blood pressure (SBP) measurements, with physicians encouraged to adjust therapy based on institutional protocols and clinical judgment. For SBP \<120 mmHg, intravenous crystalloid or colloid fluid resuscitation was prioritized. If the target blood pressure was not achieved, norepinephrine infusion was initiated at a minimum dose of 0.1 µg/kg/min and titrated up to a maximum of 0.5 µg/kg/min to maintain SBP between 120-160 mmHg (\<160 mmHg and \>120 mmHg). For SBP \>160 mmHg, intravenous or oral antihypertensive drugs were administered to reduce and maintain SBP within the 120-160 mmHg range. For SBP within the range of 120-160 mmHg, standard supportive care was provided.

Blood pressure was regulated within the elevated target management range: Blood pressure monitoring was initiated immediately upon the patient's return to the intensive care unit (ICU) postoperatively, followed by randomization. Blood pressure management was guided by systolic blood pressure (SBP) measurements, with physicians encouraged to adjust therapy based on institutional protocols and clinical judgment. For SBP \<160 mmHg, intravenous crystalloid or colloid fluid resuscitation was prioritized. If the target blood pressure was not achieved, norepinephrine infusion was initiated at a minimum dose of 0.1 µg/kg/min and titrated up to a maximum of 0.5 µg/kg/min to maintain SBP between 160-180 mmHg ( ≥160 mmHg and ≤120 mmHg). For SBP \>180 mmHg, intravenous or oral antihypertensive drugs were administered to reduce and maintain SBP within the 120-160 mmHg range. For SBP within the range of 160-180 mmHg, standard supportive care was provided.

Study summary

The goal of this clinical trial is to learn if elevating postoperative blood pressure works to improve prognosis in aneurysmal subarachnoid hemorrhage (aSAH) patients. The main questions it aims to answer are:

Does elevating postoperative blood pressure can improve the prognosis of aSAH ? What safety problems do participants have when received elevating blood pressure measurement?

Participants will:

Receive elevating or lowering blood pressure therapy in 72 hours after randomization, in order to maintain blood pressure within predefined target ranges Receive follow-up at 30 days, 90 days, and 180 days after randomization

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * 1\) Aged 18-75 years; 2\) Patients who underwent clipping or endovascular intervention within 72 hours post-ictus; 3\) Intracranial aneurysm diagnosis confirmed by operating surgeons (including neurosurgeons or neurointerventionalists) through imaging findings, intraoperative visualization, or angiography, with subarachnoid hemorrhage (SAH) attributable to the ruptured aneurysm lesion (verified via imaging, xanthochromic cerebrospinal fluid, or intraoperative observation); 4\) Hunt-Hess grade 1-4 at onset; Exclusion Criteria: * 1\) Presence of untreated intracranial aneurysms with rupture risk; 2\) Moderate-to-severe cerebral vasospasm confirmed by pre-enrollment digital subtraction angiography (DSA), transcranial Doppler (TCD), or computed tomography angiography (CTA); 3\) Intracranial massive hematoma (e.g., volume \>30 mL with midline shift \>5 mm) causing severe cerebral herniation, as evidenced by admission CT or other imaging modalities; 4\) Prior cranial neurosurgery for other central nervous system disorders; 5\) Comorbid major systemic diseases or multi-organ dysfunction with life expectancy \<1 year, potentially compromising study implementation or follow-up observations; 6\) Poorly controlled hypertension despite regular antihypertensive medication (e.g., systolic blood pressure \>160 mmHg during pharmacotherapy); 7\) Pre-onset modified Rankin Scale (mRS) score \>2 points, indicating disability from other causes; 8\) Intraoperative major complications including but not limited to massive cerebral hemorrhage, hypovolemic shock, or malignant brain swelling; 9\) Anticipated inability to complete scheduled follow-up assessments within 180 days; 10\) Pregnancy.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital, Capital Medical University Beijing Beijing Municipality

More Beijing Tiantan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07149922 on ClinicalTrials.gov ↗ ← All trials in China